In contrast, but in agreement with the known clinical effectiveness of combined treatment with atRA and ATO in patients with FLT3-ITD APL, this combination promoted all of the above parameters irrespective of the presence of the FLT3 mutation [71]. Here, FLT3 is linked to acute promyelocytic leukemia.